These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17096029)

  • 21. Gene therapy vector design strategies for the treatment of cancer.
    Dong JY; Woraratanadharm J
    Future Oncol; 2005 Jun; 1(3):361-73. PubMed ID: 16556010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor angiogenesis: biology and therapeutic prospects.
    Harris SR; Thorgeirsson UP
    In Vivo; 1998; 12(6):563-70. PubMed ID: 9891218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
    Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
    Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.
    Burrows FJ; Watanabe Y; Thorpe PE
    Cancer Res; 1992 Nov; 52(21):5954-62. PubMed ID: 1394221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization.
    Lai CM; Brankov M; Zaknich T; Lai YK; Shen WY; Constable IJ; Kovesdi I; Rakoczy PE
    Hum Gene Ther; 2001 Jul; 12(10):1299-310. PubMed ID: 11440623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-angiogenic strategies for cancer therapy (Review).
    Benouchan M; Colombo BM
    Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular-homing peptides for cancer therapy.
    Lu L; Qi H; Zhu J; Sun WX; Zhang B; Tang CY; Cheng Q
    Biomed Pharmacother; 2017 Aug; 92():187-195. PubMed ID: 28544932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging biotechnological strategies for non-viral antiangiogenic gene therapy.
    Liu C; Zhang N
    Angiogenesis; 2012 Dec; 15(4):521-42. PubMed ID: 22890617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcription-controlled gene therapy against tumor angiogenesis.
    Greenberger S; Shaish A; Varda-Bloom N; Levanon K; Breitbart E; Goldberg I; Barshack I; Hodish I; Yaacov N; Bangio L; Goncharov T; Wallach D; Harats D
    J Clin Invest; 2004 Apr; 113(7):1017-24. PubMed ID: 15057308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia, tumor endothelium, and targets for therapy.
    Teicher BA
    Adv Exp Med Biol; 2005; 566():31-8. PubMed ID: 16594131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An address system in the vasculature of normal tissues and tumors.
    Ruoslahti E; Rajotte D
    Annu Rev Immunol; 2000; 18():813-27. PubMed ID: 10837076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies.
    Dutour A; Rigaud M
    Anticancer Res; 2005; 25(6B):3799-807. PubMed ID: 16309166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical research on antiangiogenic therapy.
    Kuiper RA; Schellens JH; Blijham GH; Beijnen JH; Voest EE
    Pharmacol Res; 1998 Jan; 37(1):1-16. PubMed ID: 9503474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular targeting with phage peptide libraries.
    Pasqualini R
    Q J Nucl Med; 1999 Jun; 43(2):159-62. PubMed ID: 10429511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.
    Mahasreshti PJ; Kataram M; Wang MH; Stockard CR; Grizzle WE; Carey D; Siegal GP; Haisma HJ; Alvarez RD; Curiel DT
    Clin Cancer Res; 2003 Jul; 9(7):2701-10. PubMed ID: 12855650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
    Dang DT; Chun SY; Burkitt K; Abe M; Chen S; Havre P; Mabjeesh NJ; Heath EI; Vogelzang NJ; Cruz-Correa M; Blayney DW; Ensminger WD; St Croix B; Dang NH; Dang LH
    Cancer Res; 2008 Mar; 68(6):1872-80. PubMed ID: 18339868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites.
    Hampl M; Tanaka T; Albert PS; Lee J; Ferrari N; Fine HA
    Hum Gene Ther; 2001 Sep; 12(14):1713-29. PubMed ID: 11560766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-angiogenic gene therapy for cancer (review).
    Isayeva T; Kumar S; Ponnazhagan S
    Int J Oncol; 2004 Aug; 25(2):335-43. PubMed ID: 15254730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.